A Deep Dive into the Molecular and Immune Landscape of Undifferentiated Carcinomas with Osteoclast-like Giant Cells

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC) is a rare, distinct subtype of pancreatic carcinoma, formally classified separately from undifferentiated carcinoma (UC) of the pancreas in the World Health Organization’s 2010 and 2019 revisions. Whereas classic UC is associated with a poor prognosis and low survival rates, recent studies suggest that patients with UCOGC experience significantly longer survival and more frequent diagnosis at surgically resectable stages. Molecular profiling reveals that UCOGC consistently harbors canonical mutations in KRAS, CDKN2A, TP53, and SMAD4, aligning its classification within pancreatic ductal adenocarcinoma. In addition, UCOGC demonstrates a heterogeneous molecular landscape with distinctive mutations of uncertain biological relevance. Immunologically, UCOGC is characterized by a unique tumor microenvironment, notably a deficiency in regulatory T cells (Tregs) and a relative abundance of antigen-presenting cells. Elevated expression of PD-1 within UCOGC further suggests a potential for enhanced response to PD-1-targeted immunotherapies. Collectively, these findings underscore the need for ongoing research into the molecular and immunological characteristics of UCOGC, with the aim of identifying novel biomarkers and developing targeted treatment strategies.